BMI1 is a key component of the PRC1 (polycomb repressive complex-1) complex required for maintenance of normal and cancer stem cells. Its aberrant expression is detected in chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia (ALL), but no data exist on BMI1 requirement in ALL cells. We show here that BMI1 expression is important for proliferation and survival of Ph+ ALL cells and for leukemogenesis of Ph+ cells in vivo. Levels of BIM, interferon-α (IFNα)-regulated genes and E2F7 were upregulated in BMI1-silenced cells, suggesting that repressing their expression is important for BMI1 biological effects. Consistent with this hypothesis, we found that: (i) downregulation of BIM or E2F7 abrogated apoptosis or rescued, in part, the reduced proliferation and colony formation of BMI1 silenced BV173 cells; (ii) BIM/E2F7 double silencing further enhanced colony formation and in vivo leukemogenesis of BMI1-silenced cells; (iii) overexpression of BIM and E2F7 mimicked the effect of BMI1 silencing in BV173 and SUP-B15 cells; and (iv) treatment with IFNα suppressed proliferation and colony formation of Ph+ ALL cells. These studies indicate that the growth-promoting effects of BMI1 in Ph+ ALL cells depend on suppression of multiple pathways and support the use of IFNα in the therapy of Ph+ ALL.
INTRODUCTION p210 and p190BCR-ABL1 transform hematopoietic stem cells and/or committed lymphoid progenitors respectively, causing chronic myeloid leukemia (CML) and Ph+ acute lymphoblastic leukemia (ALL), two diseases markedly different in outcome and response to therapy. 1 Transformation by BCR-ABL1 oncogenic proteins depends on their constitutive tyrosine kinase activity and rests on the ability to activate proliferative and survival signaling pathways essential for leukemogenesis such as RAS, phosphoinositide-3 kinase/AKT and signal transducer and activator of transcription factor 5 (STAT5). [2] [3] [4] [5] [6] The tyrosine kinase activity of p190BCR-ABL1 is more potent than that of p210BCR-ABL1; 7 however, this does not explain the different outcome of CML and Ph+ ALL: 40-50% of Ph+ ALL patients express p210BCR-ABL1 and yet they may have slightly worse outcome of those expressing p190BCR-ABL1. 8, 9 An explanation for the different clinical behavior of CML and Ph+ ALL may rest in the cell of origin of the disease as BCR-ABL1-transformed hematopoietic stem cells are less prone to secondary mutations than committed B-cell progenitors. 5, 10 Some, if not all, of the secondary mutations in Ph+ ALL may be caused by aberrant RAG-dependent recombination (that is, deletion of IKAROS or the INK4A/ARF locus) and/or AIDdependent somatic hypermutation (mutation of BCL-6 or BCR-ABL1 itself). [11] [12] [13] Thus inhibiting the BCR-ABL1 kinase is insufficient to eradicate most Ph+ ALL cell clones and alternative BCR-ABL1-dependent and -independent pathways need to be targeted for an effective treatment of Ph+ ALL.
We recently found that the polycomb group family BMI1 gene 14 is required for the proliferation and colony formation of p190BCR-ABL1-transformed B cells. 15 The BMI1 protein functions as a key regulatory component of the PRC1 complex 16 and promotes the maintenance of normal and cancer stem cells. [17] [18] [19] [20] [21] Aberrant expression of BMI1 is detected in several human malignancies, 22 often correlating with metastatic disease and therapy failure. [23] [24] [25] Several findings support the importance of BMI1 in BCR-ABL1-positive leukemias, especially the lymphoid ones. First, BMI1 overexpression correlates with more advanced disease stages and with shorter time from CML chronic phase to blast crisis. 26, 27 Second, BMI1 collaborates with BCR-ABL1 in transformation of CD34 cord blood cells and these cells induce a transplantable leukemia in NOD/SCID mice with a predominant lymphoid immunophenotype. 28 Third, ectopic expression of BMI1 in BCR-ABL1-transformed hematopoietic stem cells enhanced the frequency of B-ALL-initiating cells in vitro and in mice, although BCR-ABL1 activity was still required for disease maintenance. 29 The oncogenic effects of BMI1 depend, in part, on silencing of the INK4A/ARF (CDKN2A) tumor-suppressor locus that encodes the p16 (INK4A) and p14 (alternative reading frame (ARF)) proteins. 30, 31 However, BMI1 can also exert its oncogenic effects through CDKN2A-independent pathways, 32, 33 but the precise mechanism(s) by which BMI1 overexpression contributes to Ph+ ALL, especially in cases with deletion of the INK4A/ARF locus, have yet to be elucidated.
We show here that BMI1 is required for the proliferation, survival and maintenance of Ph+ ALL cells in vitro and in mice and that the effects are mediated, at least in part, through repression of BIM and E2F7 expression and downregulation of the interferon-α (IFNα)-response pathway.
were cultured in Iscove Modified Dulbecco's Medium (Lonza Inc., Basel, Switzerland) supplemented with 10% heat-inactivated fetal bovine serum, 1% penicillin-streptomycin and 1% L-glutamine at 37°C, 5% CO 2 .
Primary Ph+ adult ALL (n = 6) or CML-lymphoid blast crisis (n = 1) cells derived from the peripheral blood (n = 2) or the bone marrow (n = 5) (average 77% blasts; range: 52-98%) were kindly provided by Dr Michael Caligiuri (Ohio State University, Columbus, OH, USA) and Dr Martin Carroll (University of Pennsylvania, Philadelphia, PA, USA) and were maintained in SFEM (Stem Cell Technologies, Vancouver, BC, Canada) supplemented with interleukin (IL)-3 (10 ng/ml), IL-7 (10 ng/ml), Flt3-L (20 ng/ml) and stem cell factor (30 ng/ml) (ProSpec, Rehovot, Israel).
Short hairpin RNA (shRNA) plasmids and lentiviral infection Control shRNA, shBMI1#1, shBMI1#2 (cloned into the inducible pLKO-Tet-On puromycin vector) and shBIM (cloned into the pLKO-Tet-On neomycin vector) were kindly provided by Dr Jagani.
34 shE2F7 (#1-4) lentiviral vectors were purchased from Applied Biological Materials (Richmond, BC, Canada).
For lentiviral infections, infectious supernatant of 293T cells transiently transfected with the indicated plasmids was collected at 48 and 72 h and used to infect BV173, SUP-B15 and primary Ph+ ALL/CML-lymphoid blast crisis cells. Twenty-four hours later, cells were subjected to antibiotic selection for 5 (puromycin; 3 μg/ml) or 14 (G418; 400 mg/ml) days.
BIM or E2F7 ectopic expression in BV173 or SUP-B15 cells
The human BIM-coding sequence was obtained by PCR from cDNA of BV173 cells with the following primers: Fw 5′-GTACTCTAGAATGGCAAAGCA ACCTTCTGA-3′ and Rv 5′-TAGAGGATCCTCAATGCATTCTCCACACC-3′. The BIM sequence was then cloned in the green fluorescent protein (GFP)-pUltra plasmid (Addgene, Cambridge, MA, USA) at the XbaI and BamHI restriction enzyme sites.
The human E2F7-coding sequence was cloned from the mammalian Gene Collection p-pCR4-TOPO-Human E2F7 sequence-verified cDNA (MHS6278-213243493 glycerol stock from Dharmacon, Lafayette, CO, USA) by PCR using the following primers: Fw 5′-AGTCTCTAGAATGGAG GTAAATTGTTTAACACTAAAA-3′ and Rv 5′-TACTGAATTCTTAGTCAGCGCC GCCG-3′. The E2F7 sequence was cloned in the GFP-pUltra plasmid at the XbaI and EcoRI restriction enzyme sites.
Three subsequent lentiviral infections were carried out as described above, and 18 h after the last infection, transduced cells were sorted based on GFP positivity and used for western blotting and colony assays after 1-2 h recovery in fresh medium.
Cell proliferation, cell cycle analysis and colony-formation assay Proliferation of shRNA-transduced BV173 and SUP-B15 cells was assessed by seeding 5 × 10 4 cells/ml with or without doxycycline (Doxy; 2.5 μg/ml; Research Product International, Mt Prospect, IL, USA) and with or without imatinib (IM; 1 μM added every 12 h) (LC Laboratories, Woburn, MA, USA) and counting the cells every 24 h by trypan blue exclusion.
Cell cycle analyses were performed by propidium iodide staining and sub-G1 cells were considered apoptotic.
For colony-formation assays, Ph+ cell lines transduced with different lentiviral shRNAs or treated with IFNα were plated in methylcellulose (Stem Cell Technologies) with or without 2.5 μg/ml Doxy (4 h of pretreatment in liquid culture and then added to the plates) and with or without IM (0.5-2 μM). Colonies were counted 6 days later. Data shown represent the mean of technical triplicates of three independent experiments. Ph+ ALL or CML-lymphoid blast crisis primary cells (lentivirus shRNA transduced or drug treated) were plated in methylcellulose supplemented with IL-3, IL-6, IL-7, Flt3-L and stem cell factor at the concentrations indicated above, and colonies were counted 10 days later. 
Microarray analysis
Total RNA was isolated from BV173 shBMI1#1 cells, untreated or treated with Doxy (2.5 μg/ml), purified with RNeasy Column (Qiagen) and used (5 μg) to generate biotin-labeled cRNA using an oligo T7 primer in a reverse transcription reaction followed by in vitro transcription reaction with biotin-labeled UTP and CTP. Ten micrograms of cRNA were fragmented and hybridized to HuGene 2.0 chip (Affymetrix, Santa Clara, CA, USA). Hybridized arrays were stained according to the manufacturer's protocols on a Fluidics Station 450 and scanned on an Affymetrix scanner 3000. Signal values were determined using the Gene Chip Operating System 1.0 (GCOS, Affymetrix). For identification of genes associated with specific biological processes, we used EPLtool, an automatic gene clustering tool developed by Wyeth Bioinformatics for Affymetrix qualifiers and Ingenuity Pathway Analysis (Qiagen).
Western blotting
Antibodies used were: anti-BMI1 (ab38295, Abcam, Cambridge, MA, USA), anti BIM (H-191), anti β-ACTIN (C4), anti-HSP90 (4F10) and anti-GRB2 (C23), all purchased from Santa Cruz Biotechnology (Dallas, TX, USA), and anti-E2F7 (ab56022, Abcam).
Statistical analyses
Data (means+s.d., three experiments) were analyzed for statistical significance by unpaired, two-tailed Student's t-test or by one-way analysis of variance. Po0.05 was considered statistically significant. Kaplan-Meier plots for mice survival experiments were generated using the Graphpad Prism software. Statistical significance of differences in survival of mice injected with control, BMI1-silenced or BMI1/BIM/E2F-7-silenced BV173 cells was assessed by log-rank test.
RESULTS
Proliferation, survival and colony formation is markedly suppressed in BMI1-silenced Ph+ ALL cells In a previous study, 15 we showed that proliferation and colony formation of SUP-B15 and Z-181 Ph+ ALL cell lines, in which BMI1 expression was downregulated by BMI1 siRNAs, was markedly suppressed compared with scramble siRNA-transfected cells. To further assess the requirement of BMI1 expression in Ph+ ALL cells and to investigate the underlying mechanisms, we generated two cell lines (BV173 and SUP-B15) expressing Doxy-inducible Bmi-1 shRNAs (#1 and #2) shown to inhibit Bmi-1 expression in multiple myeloma cells. 34 In BV173 cells, BMI1 expression was markedly decreased after a 48-h treatment with Doxy and was almost undetectable at 72 or 96 h (Supplementary Figure S1A) . Downregulation of BMI1 expression induced a decrease of viable (trypan blue-negative) BV173 cells, especially evident after a 7-day Doxy treatment (Supplementary Figure S1B) . DNA content analysis of BMI1-silenced cells revealed an increase of sub-G1, apoptotic cells and, especially in shBMI1#2 BV173 cells, a marked decrease of S-and G2-phase cells (Supplementary Figure S1C) . The increase in apoptotic cells was especially evident after a 96-h treatment with Doxy, a time point at which BMI1 expression was essentially undetectable. The effect of BMI1 silencing was also assessed by methylcellulose colony-formation assays, as shown in Supplementary Figure S1D ; BMI1-silenced BV173 cells were markedly less clonogenic than the Doxy-treated controls.
Cell counts and colony formation of BMI1-silenced SUP-B15 cells were significantly decreased compared with controls (Supplementary Figures S2A and B) ; however, the decrease in colony formation was less striking than in BV173 cells (Supplementary Figure S1D) , probably reflecting incomplete BMI1 downregulation (Supplementary Figure S2C ).
An increase in apoptotic cells was also noted in BMI1-silenced SUP-B15 cells Supplementary Figure S2D) ; consistent with the results of all other assays, apoptosis was also lower than in BV173 cells.
We also tested whether BMI1 silencing ( Figure 1a ; example of BMI1 downregulation in sample ALL#674) suppressed colony formation of primary Ph+ ALL cells; for these experiments, primary Ph+ ALL cells were transduced with the Doxy-inducible BMI1 shRNA lentiviruses and plated in methylcellulose in the presence of puromycin alone or puromycin and Doxy. Colonies were counted 10 days later. Colony formation of Doxy-treated BMI1 shRNA-transduced cells was lower than that of the corresponding untreated cells (n = 4) (Figure 1b ), in agreement with the effects in the Ph+ ALL cell lines.
As IM treatment had no effect on the expression of BMI1 in BV173 cells (Figure 2a) , we also assessed whether BMI1 silencing enhanced the inhibitory effect of IM on proliferation and colony formation of BV173 cells. Treatment with IM or with Doxy markedly reduced the number of shBMI1#1-and shBMI1#2-transduced BV173 cells compared with control cells especially after 7 days of treatment ( Figure 2b) ; however, co-treatment with IM and Doxy further reduced the number of shBMI1#1 and shBMI1#2 BV173 cells after 7 days of co-treatment (Figure 2b) .
Likewise, co-treatment with IM and Doxy was more inhibitory than either treatment on colony formation of shBMI1#1 or shBMI1#2 BV173 cells (Figure 2c ). Same effects were observed in Figure 3a) ; by contrast, mice injected with shBMI1 (#1 or #2) BV173 cells and treated with Doxy (n = 14; 7 mice/group) survived much longer (approximately 128 days) (Po0.0001) than the control mice (Figure 3a) , indicating that BMI1-regulated pathways are required for in vivo growth of BV173 cells. To assess whether death of the mice was due to the outgrowth of leukemic cells in which BMI1 expression was no longer silenced, terminally ill mice (n = 3) injected with scramble or shBMI1 BV173 cells and continuously treated with Doxy were killed, and CD10+ (BV173) cells were isolated from the bone marrow and lysed to assess BMI1 levels. Anti-BMI1 western blotting of CD10+ cell lysates revealed that BMI1 expression remained silenced upon Doxy treatment of mice injected with shBMI1 BV173 cells (Figure 3b ), suggesting that, by itself, BMI1 silencing can slow down but not suppress entirely the process of leukemia.
The effect of BMI1 silencing for in vivo leukemogenesis was also assessed in NSG mice injected with shBMI1 SUP-B15 cells. In this model, the five mice left untreated were all dead after 61 days; by contrast, the Doxy-treated mice (n = 5) survived much longer (mean survival of 97 days; P = 0.0017; Figure 3c ). Persistence of BMI1 downregulation was also noted in CD19+ cells isolated from a terminally ill Doxy-treated mouse injected with SUP-B15 cells (data not shown).
Downregulation of BIM expression rescues apoptosis but not the impaired colony formation of BMI1-silenced BV173 cells The CDKN2A locus, which is a target of BMI1-dependent repression, is deleted in the Ph+ ALL cell lines used in this study, 35 which do not express p16INK4A or p14ARF (not shown). Thus the growthinhibitory effects of BMI1 silencing in BV173 cells are INK4A/ARF independent. Previous studies in BMI1-silenced myeloma lines showed that expression of pro-apoptotic BIM is upregulated and that inhibition of BIM expression rescued, in part, the enhanced apoptosis of these cells. 34 Thus we assessed the BMI1-dependent expression and requirement of BIM in BV173 cells; as shown in Figure 4a , the expression of BIM was upregulated in BMI1-silenced BV173. Thus BV173 cells were transduced with three Doxy-inducible BIM shRNA lentiviruses and selected in the presence of G418; western blotting analysis of Doxy-treated cells revealed that BIM expression was downregulated only in cells transduced with the BIM shRNA#1 lentivirus (Supplementary Figure S4A) . Proliferation and colony-formation assays of double-silenced BMI1/BIM BV173 cells showed that cell numbers and methylcellulose colonies were identical to those of BMI1-silenced cells (Figures 4b and c) or BMI1-silenced/scramble-transduced cells (not shown), indicating that enhanced expression of BIM alone cannot explain the impaired growth of BMI1-silenced BV173 cells.
However, DNA content analysis of BMI1-and BMI1/BIM-silenced BV173 cells showed that apoptosis susceptibility (sub-G1 fraction) of BMI1-silenced cells was completely rescued by BIM downregulation (Figure 4d and Supplementary Figure S4B) , indicating that BMI1 regulates proliferation and survival of BV173 cells through different effectors. Of interest, BMI1/BIM-silenced cells exhibited an increased percentage of G1 cells, which was not evident in BMI1-silenced BV173 cells (Supplementary Figure S1) ; this observation probably reflects the increased apoptosis of these cells (Supplementary Figure S1 ) compared with BMI1/BIM doublesilenced cells in which apoptosis is completely abrogated (Figure 4d ). The accumulation of BMI1/BIM double-silenced cells in the G1 phase of the cell cycle likely explains why BIM silencing did not rescue the proliferation and colony formation of shBMI1-silenced BV173 cells.
BMI1 silencing enhances the expression of IFNα-regulated genes and E2F7 To search for INK4A/ARF-and BIM-independent pathways involved in cell cycle regulation that may explain the growth inhibition of BMI1-silenced Ph+ ALL cells, we assessed the gene expression profile of BMI1-silenced BV173 cells. For these experiments, total RNA was isolated from untreated or Doxy-treated (48 h) shBMI1#1 BV173 cells and used for oligonucleotide microarray hybridization to identify global changes in gene expression resulting from BMI1 knockdown. Treatment with Doxy almost abolished BMI1 expression Table S1 ). The volcano plot of differential expression analysis shows that most genes were centered around zero, confirming the correct normalization of the data sets (Supplementary Figure S5A) . Moreover, hierarchical clustering of differentially expressed genes in the two biological replicates of Doxy-treated vs untreated shBMI1#1 BV173 cells suggests that the two samples have distinct gene signatures (Supplementary Figure S5B) . To assess the top canonical pathways enriched in BMI1-silenced cells, we performed Ingenuity Pathway Analysis (www.ingenuity.com) on differentially expressed genes and found that the second most enriched pathway was that of the IFNα response (Supplementary Figure S6) . To further confirm this finding, changes in the expression of IFIT3 (IFN-induced protein with tetratricopeptide repeats 3), IRF-9 (IFN regulatory factor 9), IFI44 (IFN-induced 44), IFI6 (IFN-induced 6), IFIT1 (IFN-induced protein with tetratricopeptide repeats 1), 2′-5′ oligoadenylate synthetase 1 (OAS1) and E2F7 were validated by real-time PCR (Supplementary Figure S7) . E2F7 or E2F7/BIM downregulation rescues, in part or almost entirely, the growth inhibition of BMI1-silenced BV173 cells E2F7 inhibits cell proliferation by binding multiple G1/S-regulated genes and repressing their transcription and by interacting with E2F1 and blocking its transcription-activation function.
36,37 Thus we assessed whether the impaired proliferation of BMI1-silenced BV173 cells could be rescued by E2F7 silencing. Real-time PCR of shBMI1 BV173 cells transduced with different shE2F7/GFP lentiviruses revealed that E2F7 expression was downregulated only in cells transduced with the hE2F7/GFP#3 lentivirus (Supplementary Figure S8) . Proliferation and colony-formation assays of double-silenced BMI1/E2F7 BV173 cells showed that cell numbers and methylcellulose colonies were more numerous than those of BMI1-silenced cells (Figures 5a and b) , suggesting that enhanced expression of E2F7 can, in part, explain the impaired growth of BMI1-silenced BV173 cells; by contrast, apoptosis susceptibility (sub-G1 fraction) of BMI1-silenced cells was not rescued by E2F7 downregulation (not shown).
As BIM silencing did not enhance the proliferation but completely blocked the apoptosis of BMI1-silenced BV173 cells (Figure 4) , we also assessed the effects of simultaneous downregulation of BIM and E2F7 in BMI1-silenced cells. BIM/E2F7 downregulation rescued almost entirely the reduced colony formation and cell growth of BMI1-silenced BV173 cells (Figures 5b and c) , but the size of the colonies was smaller than that of untreated shBMI1/BIM/E2F-7 BV173 cells (not shown); as expected, BMI1/BIM/E2F-7-silenced BV173 cells did not undergo apoptosis (not shown).
To determine whether the molecular interplay among BMI1, BIM and E2F7 also exists in primary cells, we assessed the expression of BIM and E2F7 in BMI1-silenced Ph+ ALL cells and found increased expression of both compared with control cells (Figure 6a, ALL#1222 is shown as an example) .
Moreover, Doxy-treated NSG mice injected with shBMI1/ BIM/E2F7 BV173 cells (n = 7) exhibited a shorter survival than Doxy-treated mice injected with shBMI1 BV173 cells (median survival of 94.5 vs 128 days; P = 0.0042) (Figure 6b ). By contrast, survival of untreated mice injected with shBMI1/BIM/E2F7 BV173 cells (n = 3) was 60 days (Figure 6b) , undistinguishable from that of mice injected with parental BV173 cells or Doxy-treated mice injected with shScr BV173 cells (Figure 3a) . BIM or E2F7 overexpression mimics the effect of BMI1 silencing on colony formation of BV173 cells To further assess whether BIM and E2F7 are, at least in part, responsible for the biological effects of BMI1 silencing, BV173 or SUP-B15 cells were transduced with a pUltra lentivirus driving BIM or E2F7 expression, sorted by GFP positivity, and plated in methylcellulose. Compared with controls, BV173 cells transduced with the pUltra-BIM or the pUltra-E2F7 vector exhibited high levels of ectopic BIM or E2F7 expression (Figure 7a ) and were markedly less clonogenic (Figures 7b and c) . Similar results were obtained in pUltra-BIM-or pUltra-E2F7-transduced SUP-B15 cells (Supplementary Figure S9) .
IFNα treatment inhibits colony formation of Ph+ ALL cells As microarray analysis of BMI1-silenced BV173 cells revealed increased expression of IFNα-regulated genes (Supplementary  Table S1 ), and the activation of this pathway may also be important for the growth inhibition of BMI1-silenced BV173 cells, we performed colony-formation assays of IFNα-treated Ph+ ALL cells. As shown in Figure 8a Figure S10C) . Analysis of BMI1 and BMI1 target expression revealed that BMI1 levels were reduced after a 48-72-h treatment specially at the 10-μM drug concentration (Supplementary Figure S10D) , while inhibition of proliferation and colony formation was observed also at the 1- (Supplementary Figures S10A and B) and 0.5-μM (not shown) concentrations; of interest, expression of BIM showed a steady increase starting at 16 h during the 3-72-h PTC-209 treatment (Supplementary Figure S10D) , while RNA levels of BMI1-regulated BIM, IFNα-response genes and E2F7 in PTC-209-treated cells showed no changes or were different from those in BMI1-silenced cells (compare Supplementary Figure S7 and Supplementary Figure S10E ).
DISCUSSION
We show here that BMI1, a component of the polycomb-repressive complex 1 essential for stem cell maintenance in many cell types, is required for proliferation, survival and leukemogenesis of Ph+ ALL cells.
In particular, BMI1-silenced Ph+ ALL cells proliferated less, formed fewer colonies and exhibited enhanced sensitivity to IM treatment than control cells; and NSG mice injected with Tet-OnshBMI1 BV173 or SUP-B15 cells and treated with Doxy to silence BMI1 expression exhibited markedly prolonged survival, compared with control mice.
Of interest, ALL cells sorted from the bone marrow of terminally ill Doxy-treated mice revealed persistent downregulation of BMI1 expression, indicating that silencing BMI1 alone can only delay the BMI1 expression is known to promote tumorigenesis through transcriptional silencing of ARF (p14) and INK4A (p16) expression. 30, 31 However, the INK4A/ARF locus is homozygously deleted in the cell lines and in some of the primary Ph+ ALL samples used here, strongly suggesting that BMI1 is required by Ph+ ALL cells through INK4A/ARF-independent pathways. 32, 33 In multiple myeloma cells, the growth-promoting effects of BMI1 were also INK4A/ARF independent and were, in part, mediated through repression of the pro-apoptotic BIM gene. 34 Consistent with these findings, expression of BIM was also enhanced in BMI-silenced BV173 cells and Ph+ primary ALL cells. However, downregulating BIM expression abolished the apoptosis of BMI1-silenced cells but did not rescue their impaired proliferation and colony formation, most likely because of an increase in the fraction of G1-phase cells.
Therefore, we searched for novel BMI1-regulated genes whose modulation may explain the reduced proliferation of Ph+ ALL cells through INK4A/ARF-independent mechanisms. Of interest, expression of E2F7, a member of the E2F family with cell cycle inhibitory activity, 36, 37 and of many IFNα-responsive genes was upregulated in BMI1-silenced cells, raising the possibility that the effects of BMI1 may be due, in part, to repression of E2F7-and/or IFNα-regulated pathways. Indeed, E2F7 downregulation reversed, in part, the inhibition of cell proliferation and colony formation induced by BMI1 silencing, but apoptosis susceptibility of BMI1/E2F7-silenced cells was only rescued when BIM expression was also downregulated; moreover, E2F7/BIM downregulation accelerated the leukemogenesis of shBMI1-silenced BV173 cells, further confirming that BMI1 promotes cell growth and survival of Ph+ ALL cells through distinct pathways. In addition, overexpression of BIM or E2F7 in BV173 and SUP-B15 cells mimicked the effects of BMI1 silencing.
The observation that BMI1 silencing induced the upregulation of many IFNα-response genes suggests that the growth-promoting effects of BMI1 in Ph+ ALL cells may also depend, at least in part, on negative regulation of the IFNα-response pathway, providing a rationale for targeting this pathway. Indeed, treatment with IFNα inhibited the colony formation of primary Ph+ ALL cells and this effect was enhanced by co-treatment with IM or dasatinib; these findings support a therapeutic strategy for Ph+ ALL simultaneously targeting the BCR-ABL1 tyrosine kinase and harnessing the growthsuppressive effects of IFNα.
Despite recent improvements through integrated therapeutic approaches consisting of tyrosine kinase inhibitors, stem cell transplantation and chemotherapy, 39 most Ph+ ALL patients still have a poor outcome because of the rapid development of resistance to tyrosine kinase inhibitors. 40, 41 Few pilot studies that examined the effects of concomitant administration of IFNα with tyrosine kinase inhibitors, chemotherapy or stem cell transplantation in patients with Ph+ ALL have reported encouraging results; [42] [43] [44] however, larger patients' cohorts and longer follow-ups are necessary to determine whether IFNα has a useful role in the therapy of Ph+ ALL.
Although targeting specific BMI1-regulated pathways may be a useful approach for the therapy of Ph+ ALL, direct inhibitors of BMI1 may prove far better therapeutic agents owing to the ability to activate the full spectrum of BMI1-regulated growth-suppressive pathways.
In experiments using PTC-209, a recently discovered BMI1 smallmolecule inhibitor, 38 we found that it markedly suppressed the growth of Ph+ BV173 cells and primary Ph+ ALL cells (Supplementary Figure S10) . However, the effects were observed at drug concentrations that did not significantly reduce BMI1 levels and the expression of BMI1-regulated genes, although PTC-209 treatment induced BIM expression. The reason for these apparently contradictory findings is unclear as PTC-209 was identified in a highthroughput screening of compounds inhibiting Luciferase activity regulated by the BMI1 5′ and 3′ untranslated regions, 38 implying that decreased BMI1 expression is the primary mechanism of action of PTC-209. In a recent study, 45 treatment with PTC-209 led to a clear decrease of BMI1 expression in CML cells; this observation suggests that the difference with our findings in Ph+ ALL cells may be, perhaps, explained by cell type-specific effects influencing levels and/or kinetics of BMI1 and BMI1 targets' expression in response to PTC-209. It is also possible that the effects of PTC-209 in Ph+ ALL cells may be, in part, BMI1 independent.
In summary, we have shown here that BMI1 expression is required by Ph+ ALL cells and we have identified novel targets that appear to be mechanistically involved in its growthpromoting effects. Targeting BMI1 or essential BMI1-regulated pathways has the potential to improve the outcome of Ph+ ALL patients. 
